MedTrace Logo

Study To Evaluate The Response To Enbrel And The Impact Of Rheumatoid Factor(RF) And Anti-Cyclic Citrullinated Peptide(Anti-CCP) In Rheumatoid Arthritis(RA) Patients

NCT04428424 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1493

Last updated 2021-09-09

Study results available
· View outcomes & findings →

Summary

This study is to evaluate available local data in Iraqi patients with rheumatoid arthritis on Enbrel treatment with regards to the impact of Rheumatoid factor and Anti-cyclic citrullinated peptide using data from the Baghdad Teaching Hospital registry.

Conditions

  • Arthritis, Rheumatoid

Interventions

DRUG

Enbrel

As provided in real world practice

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-05
Primary Completion
2020-08-30
Completion
2020-08-30

Countries

  • Iraq

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04428424 on ClinicalTrials.gov